[go: up one dir, main page]

US730175A - Process of obtaining products from suprarenal glands. - Google Patents

Process of obtaining products from suprarenal glands. Download PDF

Info

Publication number
US730175A
US730175A US3554600A US1900035546A US730175A US 730175 A US730175 A US 730175A US 3554600 A US3554600 A US 3554600A US 1900035546 A US1900035546 A US 1900035546A US 730175 A US730175 A US 730175A
Authority
US
United States
Prior art keywords
glands
precipitate
product
substance
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US3554600A
Inventor
Jokichi Takamine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US3554600A priority Critical patent/US730175A/en
Priority to US37729A priority patent/US730196A/en
Priority to US37730A priority patent/US730197A/en
Priority to US42550A priority patent/US730198A/en
Priority to US138969A priority patent/US730176A/en
Application granted granted Critical
Publication of US730175A publication Critical patent/US730175A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Definitions

  • This invention relates to the production of a new product possessing the active bloodpressu re raising astringent and hemostatic characteristics and properties of the suprarenal glands in a concentrated form.
  • This new product possesses a remarkable power of raising blood-pressure of animals when in- .jected into veins and also has the property of contracting blood vessels when applied to the .vein either directly or by means of subcutaneous injection; and the invention comprises a process for producing such product in an economical and practical manner.
  • the temperature of the mixture may be raised from to centigrade.--- The mass is now strained, and the residue is pressedto squeeze out as much liquid as possible. The residue thus, pressed out is steeped again with the least amount of water to cover the mass for several hours at the same temperature as above.
  • the two extracts thus obtained are 5 mixed, and the mixture is cooled rapidly and the solidified fat removed.
  • the liquid is now small quantity of hydrogen or carbon dioxid to 100 own volu me of alcohol is added,so that the mixtu re will contain about sixty per cent. of alcohol by volume.
  • This addition of alcohol will precipitate non-active bodies, such as albuminoids, phosphates, and other mineral salts. It is then filtered and the filtrate distilled under vacuum to separate the alcohol which is condensed and recovered in a suitable manner.
  • the liquid is thus concentrated to such a degree that its specific gravity becomes 1.05 to 1.15, and caustic-soda or caustic-potash solution of about thirty per cent. strength is gradually and carefully added, taking due precaution not to overheat the liquid, until the mixture shows a strong alkaline reaction.
  • the quantity of caustic alkali to be added is regulated so that the alkali added will dissolve or redissolve the substance sought, the quantity of alkali used being about 0.3 to 0.4 per cent., in weight, of the original gland used, and the amount of ammonium chlorid to be added is regulated in such a way that it will nullify the excess of the caustic alkali used, it being understood that the solvent action is due to fixed caustic alkali and is not exerted by ammonia.
  • the caustic alkali used may be any of the substances generally recognized as of a caustic alkaline nature, as the hydrates of sodium, potassium, calcium, barium, and the like.
  • the following methods may be used, namely: The crude mass is dissolved in the least amount possible of weak acid, such as acetic or hydrochloric acid.
  • the solution is then filtered, preferably after the addition of strong alcohol to precipitate mineral matters, if necessary, and caustic ammonia or alkaline carbonates are added, so as to make the solution strongly alkaline.
  • the substance will then crystallize out in much purer-form than before, being practically free from inorganic matter. This process of recrystallization may be repeated until the substance becomes quite pure, or the crude substance may be dissolved in the least possible amount of weak caustic alkali, filtered, if necessary, and carbon dioxid is now passed into the solution.
  • White crystalline precipitate of the substance will be formed.
  • the recrystallization may be repeated as often as necessary.
  • This substance dissolves rnore readily in hot water than cold, and this property can be utilized forits recrystallization.
  • the substance is heated with water slowly to the boiling-point in presence of an excess of the substance.
  • the liquid is filtered while hot, and the filtrate on cooling will deposit the substance in fine crystalline form. It will crystallize out in tabular form or in triangular prism or fine needle form.
  • This said substance possesses all the characteristic properties ofthe suprarenal glands, being astringent and hemostatic to an extraordinary degree, as well as a powerful reducing agent.
  • aqueous solution of one to one thousand parts of water shows equal strength with the fresh aqueous extract made from fresh glands in proportion of eight parts of glands to ten of water.
  • This aqueous solution of the said substance forms a characteristic green coloration with ferric-chlorid solution when acid, and when alkaline in reaction it forms a fine carmine red. It gives ared coloration with iodin water, reduces solution of silver and gold salts,and various other chemical reactions characteristic of the suprarenal glands, this being, however, the first time that a substance has been produced possessing in permanent, concentrated, undiluted, and non-contaminated form the herein-described physiological properties, reactions, and characteristics of the suprarenal glands.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

UNITED STATES JOKICHI TAKAMINE,
PROCESS OF OBTAINING PRODUCTS FROM SUPRARENAL GLANDS. i
I Patented June 2, 1903.
on NEW YORK, N.-Y.
SPECIFICATION forming part of Letters Patent No. 730,175, dated June 2, 1903.
Application filed November 5, 1900.
such as will enable others skilled in the art to which it appertains to make and use the same.
This invention relates to the production of a new product possessing the active bloodpressu re raising astringent and hemostatic characteristics and properties of the suprarenal glands in a concentrated form. This new product possesses a remarkable power of raising blood-pressure of animals when in- .jected into veins and also has the property of contracting blood vessels when applied to the .vein either directly or by means of subcutaneous injection; and the invention comprises a process for producing such product in an economical and practical manner.
Itis a well-known and established fact that .the suprarenal glands or capsules of various.
animals, including man, contain peculiar constituents, which have remarkable astringent,
- hemostatic, and other valuable properties,
and these properties have been variously.
utilized in medical, surgical, and other arts. The usual method of. utilizing these properties is to desiccate the gland and grind the ,whole mass into powder form. In case it is desired to stop bleeding the'powder is applied to the desired spot, or to afiect the heart it may be administered through the ;mouth. 'Another form in which it is used is that of an aqueous extract. For this purpose the fresh gland may be treated with water, so as to extract the soluble constituents, and the extract thus obtained may be sterilized or treated with some antiseptic agents 'uents referred to and also that the extract while somewhat purer in comparison than the desiccated powder still contains a large percentage of foreign substance, consisting of Serial No. 35,546. (No specimens.)
a considerable deteriorating effect upon the said active constituents of the glands.
Various attempts have been made toobtain from the suprarenal glands aproduct possessing the physiological characteristics and properties herein referred to; but these attempts have failed-to produce a product f which would be permanent and contained the 3 active constituent in concentrated and isolated form free from inert and contaminating matter. By the process herein described I have succeeded in obtaining this product possessing in concentrated, permanent, undi-v luted, and uncontaminated form the hereindescribed physiological characteristics, properties, and reactions of the suprarenal glands.
In carrying out my invention I make a fluid extract of the clean suprarenal capsules from animals-such as cattle, sheep, &c.-by disintegrating the said capsules .by suitable means, then mixing with about the same Weight of water and steeping at a temperature of about to centigrade for the period of about five to ten hours in a suitable v'essel, preferably avoiding contact with atmospheric air. This'can be to a great extent accomplished by a film of fat floating on top of the liquid or may be done by passing a slow current of hydrogen or carbon dioxid into the top part of the vessel. The object ofthis is to prevent the oxidation of the extract. The fi-lm of fat referred to may conveniently be the fat naturally associated with the glands. At the latter part of the steeping the temperature of the mixture may be raised from to centigrade.--- The mass is now strained, and the residue is pressedto squeeze out as much liquid as possible. The residue thus, pressed out is steeped again with the least amount of water to cover the mass for several hours at the same temperature as above.
evaporated at a low temperature, preferably in a vacuum-pan, admitting, if necessary, a
The two extracts thus obtained are 5 mixed, and the mixture is cooled rapidly and the solidified fat removed. The liquid is now small quantity of hydrogen or carbon dioxid to 100 own volu me of alcohol is added,so that the mixtu re will contain about sixty per cent. of alcohol by volume. This addition of alcohol will precipitate non-active bodies, such as albuminoids, phosphates, and other mineral salts. It is then filtered and the filtrate distilled under vacuum to separate the alcohol which is condensed and recovered in a suitable manner. The liquid is thus concentrated to such a degree that its specific gravity becomes 1.05 to 1.15, and caustic-soda or caustic-potash solution of about thirty per cent. strength is gradually and carefully added, taking due precaution not to overheat the liquid, until the mixture shows a strong alkaline reaction.
it At this stage an amount of ammonium chlorid corresponding to one-half of the molecular weight of the caustic soda used is added and made to dissolve in the liquid. The solution is now allowed to remain in a cool place from twelve to twenty-four hours, when the formation of a crystalline substance will be observed in this liquid, and its formation will be completed during that space of time. This crystalline substance will be found to consist of conglomerations of microcrystals. The quantity of caustic alkali to be added is regulated so that the alkali added will dissolve or redissolve the substance sought, the quantity of alkali used being about 0.3 to 0.4 per cent., in weight, of the original gland used, and the amount of ammonium chlorid to be added is regulated in such a way that it will nullify the excess of the caustic alkali used, it being understood that the solvent action is due to fixed caustic alkali and is not exerted by ammonia.
The caustic alkali used may be any of the substances generally recognized as of a caustic alkaline nature, as the hydrates of sodium, potassium, calcium, barium, and the like.
Instead of adding ammonium chlorid after the addition of the caustic alkali carbon dioxid may be passed into the'solution. Then the formation of white silky microcrystals will be observed. The carbon dioxid is passed until no more precipitate is formed. This crystalline substance is filtered and washed with water and alcohol and dried. This constitutes the new product sought. This crystalline substance is difficultly soluble in water, but readily dissolves in weak alkali as well as in Weak acid. This solubility may be availed of in the step of making the fluid extract from the glands by acidulating the water used, thus obtaining the extract more readily.
In order to further purify the substance, the following methods may be used, namely: The crude mass is dissolved in the least amount possible of weak acid, such as acetic or hydrochloric acid. The solution is then filtered, preferably after the addition of strong alcohol to precipitate mineral matters, if necessary, and caustic ammonia or alkaline carbonates are added, so as to make the solution strongly alkaline. The substance will then crystallize out in much purer-form than before, being practically free from inorganic matter. This process of recrystallization may be repeated until the substance becomes quite pure, or the crude substance may be dissolved in the least possible amount of weak caustic alkali, filtered, if necessary, and carbon dioxid is now passed into the solution. White crystalline precipitate of the substance will be formed. The recrystallization may be repeated as often as necessary. This substance dissolves rnore readily in hot water than cold, and this property can be utilized forits recrystallization. For this purpose the substance is heated with water slowly to the boiling-point in presence of an excess of the substance. The liquid is filtered while hot, and the filtrate on cooling will deposit the substance in fine crystalline form. It will crystallize out in tabular form or in triangular prism or fine needle form. This said substance possesses all the characteristic properties ofthe suprarenal glands, being astringent and hemostatic to an extraordinary degree, as well as a powerful reducing agent. For instance, its aqueous solution of one to one thousand parts of water shows equal strength with the fresh aqueous extract made from fresh glands in proportion of eight parts of glands to ten of water. This aqueous solution of the said substance forms a characteristic green coloration with ferric-chlorid solution when acid, and when alkaline in reaction it forms a fine carmine red. It gives ared coloration with iodin water, reduces solution of silver and gold salts,and various other chemical reactions characteristic of the suprarenal glands, this being, however, the first time that a substance has been produced possessing in permanent, concentrated, undiluted, and non-contaminated form the herein-described physiological properties, reactions, and characteristics of the suprarenal glands.
The substance obtained as a result of my process readily combines with various acids, forming corresponding salts-such as sulfate, chlorid, phosphate, &G.-Whl0ll can be crystallized from this solution by suitable and usual means, this being again the first time a pure salt having the herein-described physiological properties, characteristics, and reactions has been obtained from the supra.- renal glands. During the manipulation with this substance it must be carefully observed to avoid oxidation from absorption of oxygen from the air, and due precautions should be taken for this purpose.
The product is not claimed in this case, but is claimed in my divisional application for Letters Patent, Serial No. 138,969, filed January 14, 1903.
Having thus described my invention, the following is what I claim as new therein and desire to secure by Letters Patent:
1. The process of obtaining the herein-described product of suprarenal glands, which consists in making a fluid extract of said glands, treating said fluid extractwitha precipitant for the non-active bodies, removing said precipitated bodies, treating'the residue with a solvent, and adding a neutralizing agent for the solvent to precipitate the said product.
2. The process of obtaining the herein-described product of suprarenal glands which consists in making an aqueous extract of the glands, precipitating from said extract the non-active bodies, removing said precipitate,
treating the remainder with a solvent, and,
adding a neutralizing agent for the solvent to precipitate the saidproduct.
3. The process of obtaining the herein-describedproduct of suprarenal glands which consists in making an aqueous extract of the glands, precipitating from said extract the non-active bodies, removing said precipitate, treating the remainder with a solvent, and adding aneutralizingagent for the solvent to precipitate the said product, said process being performed in a non-oxidizing atmostate inert albuminoids and mineral matters,
evaporating the alcohol and water to further concentrate the liquid, then'adding a solution of fixed caustic alkali, then adding ammonium chlorid to precipitate the said product in crystalline form, Washing the precipitate with suitable liquid, and drying the same, all substantially as set forth.
6. The process of obtaining the herein-de-' scribed product of suprarenal glands, which consists in steeping in water the comminuted glands at a suitable temperature for a suitable number of hours; separating the soluble matter by filtration and pressing; evaporating the filtrate to such consistency that the inert albuminoid and mineral salts will crystallize out, by addition of a suitable amount of alcohol, adding a suitable amount of alcohol to precipitate the maximum amount of inert albuminoid and mineralmatters, evaporating off the alcohol, and further evaporating the liquid to a suitable strength; adding a solutionof fixed caustic alkali, and then adding ammonium ch-lorid in sufiicient quantities to counteract the excess of caustic alkali, and allowing the solution to precipitate the said '65 product in crystalline form, separating the crystalline precipitate, Washing with water and alcohol, and drying the product, all substantially as described.
7. The process of obtaining the herein-(le 7o scribed product of suprarenal'glands, which consists in steeping in water the comminuted glands at a suitable temperature for a suitable number of hours, separating the soluble matter by filtration and pressing; evaporating the filtrate to such consistency that the, inert albuminoid and mineral salts will crystallize out, by addition of a suitable amount of alcohol, adding a suitable amount of alcohol to precipitate the maximum amount of inert albuminoid and mineral matters, distilling ofif alcohol, and further'evaporating the liquid to a suitable strength, adding a solution of fixed caustic alkali to dissolve the said product, adding a neutralizing agent to counteract the excess of fixed caustic alkali and precipitate the said product in a crystalline form, until no furtherprecipitate will be formed, Washing the precipitate with Water and alcohol and drying the pr0duct,,and then redissolving this crystalline product in a non-neutral solution, adding alcohol to precipitate mineral salts, filtering and adding a neutralizing agent to" reprecipitate thesaid product, all substan tially as described.
8. The process of refining and preparing the herein-described product of .the suprarenal glands in purer form, which consists in dissolving'the said product in dilute acetic acid, adding strong alcohol to precipitate the mineral salts that may be present, filtering the liquid and adding to it caustic ammonia .to precipitate the said product in purer form, washing the precipitate With water and alcohol and drying same, all substantially as set 1-05 forth.
9. The process of refiningand preparing the herein-described product of the suprarenal glands in purer form, which consists in dissolving the said product of the suprarenal no glands in a non-neutral solution, filtering and r I treating the solution with a neutralizing agent to precipitate the said productin a crystalline, form, filtering, washing with water and alcohol and drying, all substantially as described.
JOKICHI TAKAMINE.
Witnesses:
. J. GREEN,
A. P. KNIGHT.
US3554600A 1900-11-05 1900-11-05 Process of obtaining products from suprarenal glands. Expired - Lifetime US730175A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US3554600A US730175A (en) 1900-11-05 1900-11-05 Process of obtaining products from suprarenal glands.
US37729A US730196A (en) 1900-11-05 1900-11-26 Process of isolating the active principle of the suprarenal glands.
US37730A US730197A (en) 1900-11-05 1900-11-26 Process of isolating the active principle of the suprarenal glands.
US42550A US730198A (en) 1900-11-05 1901-01-08 Process of preparing extracts of the suprarenal glands.
US138969A US730176A (en) 1900-11-05 1903-01-14 Glandular extractive product.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3554600A US730175A (en) 1900-11-05 1900-11-05 Process of obtaining products from suprarenal glands.

Publications (1)

Publication Number Publication Date
US730175A true US730175A (en) 1903-06-02

Family

ID=2798682

Family Applications (1)

Application Number Title Priority Date Filing Date
US3554600A Expired - Lifetime US730175A (en) 1900-11-05 1900-11-05 Process of obtaining products from suprarenal glands.

Country Status (1)

Country Link
US (1) US730175A (en)

Similar Documents

Publication Publication Date Title
US1950100A (en) Chondroitin compounds and their preparation
US730175A (en) Process of obtaining products from suprarenal glands.
US3091626A (en) Method of making ferrous citrate
US2071368A (en) Process of making lactate salts and lactic acid
US730176A (en) Glandular extractive product.
US726126A (en) Mercury salts of ethylenediamin bases and process of making same.
US1616167A (en) Extraction and purification of inulin
US1602958A (en) Flavoring compound and method of making same
US1758616A (en) Method for recovering quebrachitol from rubber latex serum
US1459395A (en) Process of purifying lactic acid
US1000214A (en) Process of preparing extractive compounds of the suprarenal gland.
US449839A (en) Process of preparing pepsin
JPH05500205A (en) Hemin purification method, new hemin derivatives and their production method
US3562012A (en) Process for the preparation of pure lactulose from crude lactulosate syrups
US2198642A (en) Stable solutions of calcium thiosulphate and a process for the manufacture thereof
US676860A (en) ParaƤmidophenyl-glyoxylic acid and process of making same.
US911269A (en) Process of producing certain proteids from buttermilk.
US2190248A (en) Process for obtaining a substance lowering the blood pressure
JPS62277332A (en) Production of xylitol
US839569A (en) Iodin preparation.
US730197A (en) Process of isolating the active principle of the suprarenal glands.
US1392768A (en) Thyroid substance and process of making it
US730196A (en) Process of isolating the active principle of the suprarenal glands.
US602646A (en) Officex
US4014908A (en) Chemical process